Get the Stockscreener App
44.80
0.24%
-0.11
After Hours:
44.69
-0.11
-0.25%
Travere Therapeutics Inc stock is traded at $44.80, with a volume of 3.31M.
It is down -0.24% in the last 24 hours and up +47.17% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
See More
Previous Close:
$44.91
Open:
$45.74
24h Volume:
3.31M
Relative Volume:
1.79
Market Cap:
$4.14B
Revenue:
$490.73M
Net Income/Loss:
$-50.26M
P/E Ratio:
-74.30
EPS:
-0.603
Net Cash Flow:
$-20.37M
1W Performance:
+9.56%
1M Performance:
+47.17%
6M Performance:
+32.86%
1Y Performance:
+109.25%
1-Day Range:
$43.06
$48.61
1-Week Range:
$39.75
$48.61
52-Week Range:
$13.88
$48.61
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
44.80 | 4.15B | 490.73M | -50.26M | -20.37M | -0.603 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Director plans sale of 2,181 shares after RSU vesting (NASDAQ: TVTX) - Stock Titan
Insider sells shares; TVTX (NASDAQ: TVTX) files Form 144 reporting RSU vesting - Stock Titan
Jula Inrig sells 20,000 shares (NASDAQ: TVTX) — Form 144 filing - Stock Titan
Insider sale filing — TVTX (NASDAQ: TVTX) Peter Heerma sold 7,215 shares - Stock Titan
Travere Therapeutics plans $400 million convertible notes offering - Investing.com
Roy Baynes files sale of 4,500 shares (NASDAQ: TVTX) under Rule 144 - Stock Titan
Travere Therapeutics plans $400 million convertible notes offering By Investing.com - Investing.com Australia
Travere Therapeutics plans $400M convertible notes offering - MSN
Travere Therapeutics (NASDAQ: TVTX) seeks $400M convertible notes - Stock Titan
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes - The Joplin Globe
Travere lines up $400M debt sale, aims to repurchase 2029 notes - Stock Titan
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings - Benzinga
MSN Money - MSN
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2026 Earnings Call Transcript - Insider Monkey
Travere Therapeutics price target raised to $57 from $47 at H.C. Wainwright - TipRanks
Travere Therapeutics, Inc. Q1 2026: Financial Results, Risk Factors, and Management Discussion - Minichart
Travere Therapeutics Reports First Quarter 2026 Financial Results - BioSpace
Travere Therapeutics Inc SEC Filings - Stock Titan
How (TVTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Why Travere Therapeutics (TVTX) Is Up 10.0% After Stronger Q1 2026 Results And Narrower Loss - simplywall.st
Travere Therapeutics Bets Big on FILSPARI Momentum - TipRanks
Travere Therapeutics : Investor Fact Sheet - marketscreener.com
Travere Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Travere Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
TVTX: FILSPARI's FDA approval in FSGS fueled record Q1 sales and positions for rapid future growth - TradingView
Travere Therapeutics (TVTX) reports Q1 loss, misses revenue estimates - MSN
TVTX: Record Filspari sales and first FSGS approval drive strong growth and outlook - TradingView
Travere (TVTX) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Travere Q1 2026 sees mixed results, stock rises - Investing.com Australia
Travere Therapeutics reports Q1 EPS 5c, consensus (5c) - TipRanks
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance Singapore
Travere Therapeutics Q1 Swings to Profit, Revenue Rises - marketscreener.com
Travere Therapeutics : Q1 2026 Earnings Presentation - marketscreener.com
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Travere therapeutics director Roy Baynes sells $431,145 in stock. By Investing.com - Investing.com Canada
Travere Therapeutics (NASDAQ: TVTX) grows FILSPARI sales as FDA fully approves FSGS use - Stock Titan
Travere Therapeutics 1Q 2026: Revenue $127.2M, EPS ($0.4) — 10-Q Summary - TradingView
TVTX: FILSPARI sales drove 56% revenue growth and improved net loss, with strong liquidity maintained - TradingView
Travere Therapeutics falls on revenue miss despite record demand By Investing.com - Investing.com Australia
Travere Therapeutics falls on revenue miss despite record demand - Investing.com
Travere therapeutics director Roy Baynes sells $431,145 in stock. - Investing.com
Q1 2026 Travere Therapeutics Inc Earnings Call Transcript - GuruFocus
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q1 Adjusted EPS $0.05 per Share - marketscreener.com
Travere Therapeutics (TVTX) director sells 9,750 shares via 10b5-1 plan - Stock Titan
Earnings Flash (TVTX) Travere Therapeutics, Inc. Reports Q1 Revenue $127.2M, vs. FactSet Est of $136.2M - marketscreener.com
Travere: Q1 Earnings Snapshot - wwltv.com
FILSPARI growth lifts Travere (NASDAQ: TVTX) to Q1 2026 non-GAAP profit - Stock Titan
20,000-share sale notice for Morgan Stanley Smith Barney (TVTX) via option exercise - Stock Titan
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
TVTX (NASDAQ) files Rule 144 for 20,000-share option exercise; prior April sales listed - Stock Titan
Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):